# Ascentage Pharma Group International: Form 20-F for the period ended Dec 31, 2024

- Company: [Ascentage Pharma Group International](/companies/aapg.md) (CIK 2023311)
- Form: 20-F
- Filed: 2025-04-16
- Accepted by EDGAR: Apr 16, 2025, 16:30 ET
- Period: 2024-12-31
- Accession: 0001213900-25-032599
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/ea0233422-20f_ascentage.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-01-01 to 2024-12-31 | $134.3m | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2024-01-01 to 2024-12-31 | $4.0m | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2024-01-01 to 2024-12-31 | $130.4m | ifrs-full:GrossProfit |
| Income tax | 12 months, 2024-01-01 to 2024-12-31 | $1.4m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | −$55.5m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.18 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.18 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | −$15.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | $3.3m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2024-12-31 | $122.4m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2024-12-31 | $202.0m | ifrs-full:CurrentAssets |
| Current liabilities | at 2024-12-31 | $159.8m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2024-12-31 | $321.1m | ifrs-full:Liabilities |
| Shareholders' equity | at 2024-12-31 | $36.2m | ifrs-full:EquityAttributableToOwnersOfParent |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/ea0233422-20f_ascentage.htm

Filed Apr 16, 2025.
Source: SEC EDGAR, the filing index for accession 0001213900-25-032599. Last ingested by Listed: Nov 5, 2026, 12:38 ET. No prices; not investment advice.